Table 2.
Clinical trials investigating the efficacy of PARP inhibitors in various solid malignancies are increasing, with a majority currently in progress.
| Trial Name | Status | Conditions | Phase | Results Summary |
|---|---|---|---|---|
| Efficacy and Safety of PARPi to Treat Pancreatic Cancer | Unknown | Pancreatic Cancer | Phase II | None available yet |
| Survival Data and Characteristics of Finisterian Patients Treated with PARP Inhibitors for Ovarian Cancer Between 2014 and 2019 | Completed | Ovarian Neoplasm | Does not specify | None available |
| Pamiparib in Fusion Positive, Reversion Negative HGSOC or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on PARPI or Chemotherapy | Recruiting | Ovarian Cancer Carcinosarcoma |
Phase II | None available yet |
| A Study to Examine Olaparib Maintenance Retreatment in Patients with Epithelial Ovarian Cancer | Active, not recruiting | Epithelial Ovarian Cancer | Phase III | None available yet |
| Study of M4344 in Combination with Niraparib | Not yet recruiting | Advanced Solid Tumor Breast Cancer |
Phase I Phase II |
None available yet |
| Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors | Recruiting | Breast Cancer | Early Phase I | None available yet |
| Olaparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer | Active, not recruiting | Ovarian Cancer | Phase I Phase II |
None available yet |
| Recurrent Ovarian Carcinosarcoma Anti-pd-1 Niraparib | Recruiting | Ovarian Carcinosarcoma Endometrial Carcinosarcoma |
Phase II Phase III |
None available yet |
| ATR Inhibitor BAY 1895344 Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer | Recruiting | Advanced Solid Tumors (excluding prostate cancer) Ovarian Cancer |
Phase I | None available yet |
| The Clinical Markers for PARP Inhibitors-related Efficacy in Ovarian Cancer | Recruiting | Ovarian Cancer | Does not specify | None available yet |
| Platinum and PARPI for Neoadjuvant Treatment of Triple Negative Breast Cancer (TNBC) and/or Germline BRCA (gBRCA) Positive Breast Cancer | Recruiting | Breast Cancer | Phase II Phase III |
None available yet |
| Induction and Maintenance Treatment with PARP Inhibitor and Immunotherapy in HPV-negative HNSCC | Recruiting | Head and Neck Squamous Cell Carcinoma | Phase II | None available yet |
| Stratified Evaluation of PDS and NACT-IDS in Ovarian Cancer (FOCUS) | Not yet recruiting | Epithelial Ovarian Cancer Fallopian Tube Cancer Primary Peritoneal Carcinoma |
Phase III | None available yet |
| Niraparib Maintenance in Patients with Advanced Ovarian Cancer at Neoadjuvant Setting | Recruiting | Ovarian Cancer | Phase II | None available yet |
| Combination of HX008 and Niraparib in Germ-line-mutated Metastatic Breast Cancer | Not yet recruiting | Breast Cancer | Phase II | None available yet |
| Pembrolizumab and Olaparib in Recurrent/Metastatic, Platinum Resistant Nasopharyngeal Cancer | Not yet recruiting | Nasopharyngeal Carcinoma | Phase II | None available yet |
| Anlotinib and Niraparib Dual Therapy Evaluation in Platinum-resistant Recurrent Ovarian Cancer | Recruiting | Platinum-Resistant Ovarian Cancer | Phase II | None available yet |
| Multi-maintenance Olaparib After Disease Recurrence in Participants with Platinum Sensitive BRCA HGSOC | Active, not recruiting | Ovarian Cancer | Early Phase I | None available yet |
| Olaparib After Response to Trabectedin-pegylated Liposomal Doxorubicin in Recurrent Ovarian Carcinoma | Active, not recruiting | Ovarian Cancer | Phase II | None available yet |
| Investigation of 2X-121 in Patients with Advanced Ovarian Cancer Selected by the 2X-121 DRP | Recruiting | Advanced Ovarian Cancer | Phase II | None available yet |
| DVAC/OvCa and Standard of Care (SoC) in Relapsed Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma | Not yet recruiting | Ovarian Cancer Fallopian Tube Cancer Peritoneal Cancer |
Phase III | None available yet |
| A Study of Niraparib in Patients with Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens | Active, not recruiting | Ovarian Neoplasms Ovarian Cancer |
Phase II | Of 463 participants who received Niraparib, 122 completed study. Of 47 patients in primary efficacy population, 13 (28%) achieved overall response [159] |
| Olaparib and Temozolomide in Treating Patients with Advanced, Metastatic, or Unresectable Uterine Leiomyosarcoma | Active, not recruiting | Stage III–IV Uterine Corpus Leiomyosarcoma | Phase II | None available yet |
| Analysis of the Clinical Experience with Rucaparib in the Rucaparib Access Program (RAP) in Spain—A GEICO Study | Recruiting | Epithelial Ovarian Cancer Fallopian Tube Cancer Primary Peritoneal Cancer |
Does not specify | None available yet |
| A Study to Evaluate Rucaparib in Patients with Solid Tumors and With Deleterious Mutations in HRR Genes | Recruiting | Solid Tumor | Phase II | None available yet |
| A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy | Active, not recruiting | Epithelial Ovarian Cancer Primary Peritoneal Fallopian Tube Cancer |
Phase III | None available yet |
| A Study of Rucaparib Versus Physician’s Choice of Therapy in Patients with Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency | Recruiting | Metastatic Castration-Resistant Prostate Cancer | Phase III | None available yet |
| A Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency | Active, not recruiting | Metastatic Castration-Resistant Prostate Cancer | Phase II | None available yet |
| A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer | Recruiting | Triple -Negative Breast Cancer | Phase II | None available yet |
| An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies | Active, not recruiting | Prostatic neoplasms | Phase II | None available yet |
| Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents | Recruiting | Advanced Solid Malignancies—Head and Neck Squamous Cell Carcinoma, ATM Pro/Deficient Non-Small-Cell Lung Cancer, Gastric, Breast, and Ovarian Cancer | Phase I Phase II |
None available yet |
| Olaparib With or Without Atezolizumab in Treating Patients With Locally Advanced Unresectable or Metastatic Non-HER2-Positive Breast Cancer | Recruiting | Locally Advanced Unresectable Breast Carcinoma Metastatic Breast Carcinoma Stage III–IV Breast Cancer |
Phase II | None available yet |
| Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer | Recruiting | Metastatic Pancreatic Ductal Adenocarcinoma Stage IV Pancreatic Cancer |
Phase II | None available yet |